BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Body Protective Compound-157) referenced across tendon, ligament, gastric-tissue, soft-tissue and angiogenesis research literature — the category benchmark in healing and recovery research peptides. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, and not TGA-approved. No performance or human-use claim is made about it.

What research is BPC-157 associated with?

Pathway research on BPC-157 is synthesised in the review by Seiwerth and colleagues (Frontiers in Pharmacology, 2021), covering its reported interaction with the nitric-oxide system and VEGFR2-associated angiogenic signalling. The pro-angiogenic mechanism (the VEGFR2–Akt–eNOS axis) was reported by Hsieh and colleagues (Journal of Molecular Medicine, 2017), and Chang and colleagues (Journal of Applied Physiology, 2011) linked BPC-157 to tendon-fibroblast outgrowth via the FAK–paxillin pathway. It is studied in vitro as a research tool, not as a treatment.

Is BPC-157 TGA-approved in Australia?

No. BPC-157 is not TGA-approved and is not a therapeutic good. It is supplied strictly for in-vitro and laboratory research use only, with no medical, performance, or human-use claim.

How is BPC-157 reconstituted and stored for research use?

The lyophilised vial is reconstituted with bacteriostatic water for laboratory handling — for example, a 5mg vial in 2mL yields a 2.5mg/mL working stock. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window.

How is BPC-157 shipped in Australia?

Stock is held and dispatched AU-domestic — no inbound customs handling. Free shipping over $100; orders placed before 12pm AEST are dispatched the same business day. Supplied strictly for laboratory research use only.

[ Healing & recovery research ]

BPC-157 in Australia: a soft-tissue research guide

What BPC-157 is — the 15-residue pentadecapeptide that is the category benchmark across tendon, ligament, gastric-tissue and angiogenesis research — how it is referenced alongside TB-500, and how research-grade material is HPLC-verified. A laboratory research reference for Australian researchers.

8 min read · Updated 22 July 2026

BPC-157 research peptide vial — 5mg / 10mg, independently HPLC-tested, COA on file

[ Research use only · Not for human consumption ]

BPC-157 in Australia. BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Body Protective Compound-157) studied across the soft-tissue, tendon, ligament, gastric and angiogenesis research literature — the category benchmark cited in nearly every research-peptide catalogue. This guide is a research-reference summary for Australian researchers. It makes no performance, medical, or human-use claim.

What BPC-157 is

BPC-157 (a 15-residue pentadecapeptide, sequence GEPPPGKPADDAGLV) is a partial sequence derived from research on a stable gastric-juice protective protein. It is one of the most-studied compounds in the research-peptide literature, referenced across tendon and ligament cytoprotection, gastric-mucosal, angiogenic and broader soft-tissue-repair research.

Pathway research on BPC-157

Pathway research on BPC-157 is synthesised in the review by Seiwerth and colleagues (Frontiers in Pharmacology, 2021), which covers its reported interaction with the nitric-oxide system and its VEGFR2-associated angiogenic signalling. The pro-angiogenic mechanism — up-regulation and activation of the VEGFR2–Akt–eNOS axis — was reported by Hsieh and colleagues (Journal of Molecular Medicine, 2017). In tendon-cell research, Chang and colleagues (Journal of Applied Physiology, 2011) linked BPC-157 to tendon-fibroblast outgrowth, survival and migration through the FAK–paxillin pathway. It is studied in vitro as a research tool, not as a treatment.

The canonical TB-500 pairing

BPC-157 is most frequently referenced alongside TB-500 (thymosin β-4) in the canonical “soft-tissue” research pair — the two act on distinct pathways (growth-factor / nitric-oxide signalling versus actin dynamics) that converge on the tissue-repair research model. See the TB-500 research guide for the actin-dynamics partner, or the BPC-157 + TB-500 “Wolverine stack” guide for the co-lyophilised pairing in a single vial.

Identity, purity and the COA moat

Every batch of BPC-157 supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the BPC-157 product page and in the lab-reports library — a real batch number, the measured percentage rather than a marketing figure, and an independently verifiable Janoshik report. BPC-157 is stocked in 5mg and 10mg lyophilised vials; nothing is listed without a certificate on file.

Reconstitution, handling and compliance

BPC-157 ships as a lyophilised powder. Reconstitute with bacteriostatic water for laboratory handling — a 5mg vial in 2mL yields a 2.5mg/mL working stock. Store the powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window. BPC-157 is not TGA-approved and is not a therapeutic good; Elite AU Peptides makes no medical, performance, or human-use claim, and supplies it strictly for in-vitro and laboratory research use only. Researchers should consult primary peer-reviewed sources for pathway data.

[ Frequently asked ]

Healing & recovery research — questions researchers ask.

What is BPC-157?: BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Body Protective Compound-157) referenced across tendon, ligament, gastric-tissue, soft-tissue and angiogenesis research literature — the category benchmark in healing and recovery research peptides. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, and not TGA-approved. No performance or human-use claim is made about it.
What research is BPC-157 associated with?: Pathway research on BPC-157 is synthesised in the review by Seiwerth and colleagues (Frontiers in Pharmacology, 2021), covering its reported interaction with the nitric-oxide system and VEGFR2-associated angiogenic signalling. The pro-angiogenic mechanism (the VEGFR2–Akt–eNOS axis) was reported by Hsieh and colleagues (Journal of Molecular Medicine, 2017), and Chang and colleagues (Journal of Applied Physiology, 2011) linked BPC-157 to tendon-fibroblast outgrowth via the FAK–paxillin pathway. It is studied in vitro as a research tool, not as a treatment.
How does BPC-157 pair with TB-500?: BPC-157 and TB-500 (thymosin β-4) are the canonical “soft-tissue” research pair — they act on distinct pathways (growth-factor / nitric-oxide signalling versus actin dynamics) that converge on the tissue-repair research model, so they are frequently referenced together. See the TB-500 guide for the actin-dynamics partner, or the BPC-157 + TB-500 “Wolverine stack” guide for the co-lyophilised pairing.
Is BPC-157 TGA-approved in Australia?: No. BPC-157 is not TGA-approved and is not a therapeutic good. It is supplied strictly for in-vitro and laboratory research use only, with no medical, performance, or human-use claim.
How is research-grade BPC-157 tested?: Every batch is independently HPLC-tested by Janoshik Analytical before it is listed. The measured purity is published on the product page and in the lab-reports library — a real batch number, the measured percentage, and an independently verifiable Janoshik report; nothing is listed without a certificate on file.
How is BPC-157 reconstituted and stored for research use?: The lyophilised vial is reconstituted with bacteriostatic water for laboratory handling — for example, a 5mg vial in 2mL yields a 2.5mg/mL working stock. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window.
How is BPC-157 shipped in Australia?: Stock is held and dispatched AU-domestic — no inbound customs handling. Free shipping over $100; orders placed before 12pm AEST are dispatched the same business day. Supplied strictly for laboratory research use only.

[ Referenced in this guide ]

Shop the compounds

[ Keep reading ]

More research guides

Elite AU Peptides supplies research peptides and related compounds for laboratory and in-vitro research use only. Products are not therapeutic goods, are not TGA-approved, and are not for human or animal consumption. Nothing on this site constitutes medical advice or a therapeutic claim. Purchasers must be 18 years or older and are responsible for complying with all applicable laws in their jurisdiction.